HHV-6A, 6B, and 7: pathogenesis, host response, and clinical disease

Yasuko Mori; Koichi Yamanishi

HHV-6A, 6B, and 7: pathogenesis, host response, and clinical disease

Review

In: Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007. Chapter 46.

Authors

Yasuko Mori¹, Koichi Yamanishi¹

Book Editors

Ann Arvin¹, Gabriella Campadelli-Fiume², Edward Mocarski³, Patrick S. Moore⁴, Bernard Roizman⁵, Richard Whitley⁶, Koichi Yamanishi⁷

Affiliation

¹ Department of Microbiology, Osaka University Graduate School of Medicine, Japan

Book Affiliations

¹ Stanford University, CA School of Medicine
² University of Bologna, Italy
³ Emory University School of Medicine, USA
⁴ University of Pittsburgh Cancer Institute, PA, USA
⁵ The University of Chicago, IL, USA
⁶ University of Alabama at Birmingham, AL, USA
⁷ Osaka University School of Medicine, Japan

PMID: 21348085
Bookshelf ID: NBK47394

Excerpt

Human herpesvirus 6(HHV-6) is a human pathogen of emerging clinical significance. HHV-6 was first isolated from patients with lymphoproliferative disorders in 1986 (Salahuddin et al., 1986). HHV-6 isolates are classified into two groups as variants A(HHV-6A) and variant B(HHV-6B) (Schirmer et al., . The two variants are closely related but show consistent differences in biological, immunological, epidemiological, and molecular properties. HHV-6B is the major causative agent of exanthem subitum (ES) (Yamanishi et al., 1988), but no clear disease has yet been associated with HHV-6A.

Sections

Publication types

Review